BIOA Fundamental Analysis - BIOAGE LABS INC

Fundamental Rating

BIOA gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 196 industry peers in the Pharmaceuticals industry. No worries on liquidiy or solvency for BIOA as it has an excellent financial health rating, but there are worries on the profitability. BIOA is valued expensive and it does not seem to be growing.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year BIOA has reported negative net income.

BIOA had a negative operating cash flow in the past year.

1.2 Ratios

BIOA's Return On Assets of -24.53% is in line compared to the rest of the industry. BIOA outperforms 56.63% of its industry peers.

BIOA has a better Return On Equity (-26.81%) than 61.73% of its industry peers.

		Industry Rank	Sector Rank
ROA	-24.53%
ROE	-26.81%
ROIC	N/A

ROA(3y)-135.29%

ROA(5y)N/A

ROE(3y)N/A

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

BIOA does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

The number of shares outstanding for BIOA has been increased compared to 1 year ago.

BIOA has a better debt/assets ratio than last year.

2.2 Solvency

An Altman-Z score of 2.75 indicates that BIOA is not a great score, but indicates only limited risk for bankruptcy at the moment.

With a decent Altman-Z score value of 2.75, BIOA is doing good in the industry, outperforming 70.41% of the companies in the same industry.

BIOA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Altman-Z	2.75

ROIC/WACCN/A

WACCN/A

2.3 Liquidity

A Current Ratio of 13.21 indicates that BIOA has no problem at all paying its short term obligations.

BIOA has a better Current ratio (13.21) than 86.73% of its industry peers.

A Quick Ratio of 13.21 indicates that BIOA has no problem at all paying its short term obligations.

BIOA has a Quick ratio of 13.21. This is amongst the best in the industry. BIOA outperforms 86.73% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	13.21
Quick Ratio	13.21

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The earnings per share for BIOA have decreased by -6.13% in the last year.

EPS 1Y (TTM)-6.13%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%22.66%

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 19.52% on average over the next years. This is quite good.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

EPS Next Y72.78%

EPS Next 2Y29.98%

EPS Next 3Y19.52%

EPS Next 5YN/A

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

BIOA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for BIOA. No positive earnings are expected for the next year.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

BIOA's earnings are expected to grow with 19.52% in the coming years. This may justify a more expensive valuation.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y29.98%

EPS Next 3Y19.52%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

BIOA does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

BIOAGE LABS INC

NASDAQ:BIOA (9/24/2025, 12:38:26 PM)

5.14

+0.2 (+4.05%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryPharmaceuticals

Earnings (Last)08-06 2025-08-06/amc

Earnings (Next)11-07 2025-11-07

Inst Owners64.03%

Inst Owner Change2.49%

Ins Owners3.64%

Ins Owner Change0%

Market Cap184.27M

Analysts46.67

Price Target4.76 (-7.39%)

Short Float %6.95%

Short Ratio17.13

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)1

Avg EPS beat(2)5.44%

Min EPS beat(2)-22.35%

Max EPS beat(2)33.23%

EPS beat(4)2

Avg EPS beat(4)-198.03%

Min EPS beat(4)-810.1%

Max EPS beat(4)33.23%

EPS beat(8)N/A

Avg EPS beat(8)N/A

EPS beat(12)N/A

Avg EPS beat(12)N/A

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)N/A

Avg Revenue beat(2)N/A

Min Revenue beat(2)N/A

Max Revenue beat(2)N/A

Revenue beat(4)N/A

Avg Revenue beat(4)N/A

Min Revenue beat(4)N/A

Max Revenue beat(4)N/A

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)0%

PT rev (3m)0%

EPS NQ rev (1m)0%

EPS NQ rev (3m)-13.04%

EPS NY rev (1m)0%

EPS NY rev (3m)-13.53%

Revenue NQ rev (1m)0%

Revenue NQ rev (3m)34.05%

Revenue NY rev (1m)0%

Revenue NY rev (3m)84.5%

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	47.7
P/FCF	N/A
P/OCF	N/A
P/B	0.63
P/tB	0.63
EV/EBITDA	N/A

EPS(TTM)-9.63

EYN/A

EPS(NY)-2.56

Fwd EYN/A

FCF(TTM)-1.63

FCFYN/A

OCF(TTM)-1.6

OCFYN/A

SpS0.11

BVpS8.22

TBVpS8.22

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-24.53%
ROE	-26.81%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM	N/A

ROA(3y)-135.29%

ROA(5y)N/A

ROE(3y)N/A

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexcg growth 3YN/A

ROICexcg growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

F-Score6

Asset Turnover0.01

Health

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	508.89%
Cap/Sales	23.71%
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	13.21
Quick Ratio	13.21
Altman-Z	2.75

F-Score6

WACCN/A

ROIC/WACCN/A

Cap/Depr(3y)133.82%

Cap/Depr(5y)N/A

Cap/Sales(3y)N/A

Cap/Sales(5y)N/A

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)-6.13%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%22.66%

EPS Next Y72.78%

EPS Next 2Y29.98%

EPS Next 3Y19.52%

EPS Next 5YN/A

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%N/A

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

EBIT growth 1Y-61.56%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next Year-3.31%

EBIT Next 3Y-13.29%

EBIT Next 5YN/A

FCF growth 1Y-38.26%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y-37.9%

OCF growth 3YN/A

OCF growth 5YN/A

BIOAGE LABS INC (BIOA) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens